Tyra Biosciences Inc (TYRA) Stock Price, Quote & News

Company Profile

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 728 4760

Website: tyra.bio

Address:

2656 State Street, Carlsbad, United States

anachartanalyst Dec. 16 at 8:02 PM

$TYRA https://anachart.com/wp-content/uploads/ana_temp/1765915319_soc-img.jpg

0 · Reply

JarvisFlow Dec. 16 at 12:36 PM

Wedbush updates rating for Tyra Biosciences ( $TYRA ) to Outperform, target set at 30 → 37.

0 · Reply

Quantumup Dec. 16 at 12:14 PM

Wedbush Added $TYRA to their Best Idea List while⬆️the PT to $37 from $30 and reiterating at an Outperform rating. $URGN $JNJ $BBIO $ASND SNY BMRN Wedbush said—We are adding TYRA to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Ph 2 studies in intermediate-grade non-muscle invasive bladder cancer (IR-NMIBC) (1H:26) and in achondroplasia (ACH) (2H:26). TYRA also recently announced plans to initiate a Ph 2 study in upper tract urothelial carcinoma (UTUC) in 2026, which we believe is an underappreciated opportunity and a potential fast-to-market strategy. We are increasing our price target to $37 (from $30) as we realign our model away from the metastatic UC setting to UTUC, and update timelines based on recent guidance.

0 · Reply

Quantumup Dec. 4 at 1:26 PM

Goldman Sachs🏁 $TYRA at an Early-Stage Biotech rating. $BBIO $JNJ $INCY $OTSKY Here's what Goldman Sachs had to say in its initiation report: https://x.com/Quantumup1/status/1996570205779099845?s=20

0 · Reply

destinyb5 Dec. 3 at 6:18 PM

$TYRA $SPY

0 · Reply

PaulLaurent Nov. 24 at 8:06 AM

🔥 Short Squeeze Radar (ORTEX scores) — This Week $TYRA – 80,60/100. Elevated setup; watch borrow fees/locates and VWAP/pivot reclaims. $EPSM – 80,78/100. Recent runner profile; look for higher-low structure and volume persistence. $QMMM – 68,05/100. Mid-tier; needs strong volume and a clean reclaim to trigger. $NVRI – 63,11/100. Lower-tier risk; likely needs a fresh catalyst plus tight borrow to squeeze. $SGML – 73,84/100. Theme-sensitive; monitor borrow dynamics and headline flow for acceleration. Plan: Focus on VWAP/pivot reclaims, scale into strength on clean squeezes, and keep stops tight if borrow loosens or momentum stalls.

1 · Reply

BEATOFtheMARKET Nov. 23 at 9:09 PM

$TWST $TXG $TXT $TYLG 🔥 $TYRA 🔥

0 · Reply

FinJay Nov. 23 at 3:01 PM

🚀 5 Stocks With Strong Short-Squeeze Potential 🔥 High risk, high reward plays worth watching: $SGML $NVRI $QMMM $EPSM $TYRA 🎥 Watch now: https://youtu.be/aD2zQJ236To #stocks #shortsqueeze #investing

1 · Reply

monkfruit Nov. 21 at 4:46 PM

$TYRA Sold for a 51.64% gain. 🤯 This stock way outperformed my expectations. Might keep going up, but I'm happy here. https://stocktwits.com/monkfruit/message/628677685

0 · Reply

StockScanners Nov. 21 at 4:30 AM

$TYRA keep watch if this holds above 20.35

0 · Reply

Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Tyra Biosciences Announces Participation at Upcoming Investor Events

Nov 5, 2025, 4:05 PM EST - 7 weeks ago

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

Aug 21, 2025, 8:00 AM EDT - 4 months ago

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Aug 14, 2025, 4:05 PM EDT - 4 months ago

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

Jul 21, 2025, 4:05 PM EDT - 5 months ago

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

Jul 8, 2025, 4:05 PM EDT - 6 months ago

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

Jun 30, 2025, 8:00 AM EDT - 6 months ago

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

May 12, 2025, 4:05 PM EDT - 8 months ago

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 8, 2025, 4:05 PM EDT - 8 months ago

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Feb 11, 2025, 4:05 PM EST - 11 months ago

Tyra Biosciences to Present at Upcoming Investor Conferences

Jan 22, 2025, 8:00 AM EST - 1 year ago

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Jan 10, 2025, 8:00 AM EST - 1 year ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Nov 7, 2024, 4:05 PM EST - 1 year ago

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Oct 25, 2024, 11:34 AM EDT - 1 year ago

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?

Oct 24, 2024, 6:21 PM EDT - 1 year ago

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Oct 23, 2024, 4:05 PM EDT - 1 year ago

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Oct 21, 2024, 7:55 AM EDT - 1 year ago

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Oct 18, 2024, 2:34 PM EDT - 1 year ago

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

Oct 18, 2024, 9:51 AM EDT - 1 year ago

This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

DDOG ACI ECL VCTR

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Sep 12, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 4:00 AM EDT - 1 year ago

Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Sep 9, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate

Sep 7, 2024, 11:00 AM EDT - 1 year ago

Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Sep 6, 2024, 11:00 AM EDT - 1 year ago

Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations

Sep 5, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join

$The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Possible Securities Related Infractions And Stockholders Can Assist$

Sep 4, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Possible Securities Related Infractions And Stockholders Can Assist

Sep 2, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences Inc Stockholders Can Partake In An Inquiry Into Whether The Company Defrauded The Public

Sep 1, 2024, 11:00 AM EDT - 1 year ago

Attention Investors: The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Potentially Violating Securities Laws And Investors Can Reach Out

Aug 31, 2024, 11:00 AM EDT - 1 year ago

An Inquiry Is Being Made Into Whether Tyra Biosciences Has Defrauded The Public And The Schall Law Firm Wants Shareholders To Help

Aug 30, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences May Have Broken Securities Laws And Impacted Stakeholders Are Urged To Lend A Hand To The Schall Law Firm's Inquiry

Aug 29, 2024, 11:00 AM EDT - 1 year ago

The Public Is Encouraged To Reach Out To The Schall Law Firm About An Inquiry Into Tyra Biosciences Inc.'s Potentially Fraudulent Actions

Aug 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Invites Investors In Tyra Biosciences Inc To Partake In An Investigation Into Securities Fraud

Aug 27, 2024, 11:00 AM EDT - 1 year ago

An Inquiry Has Been Opened Into Tyra Biosciences Inc's Possible Securities Related Impropriety And Impacted Stakeholders Should Join

Aug 25, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Inquiring Into Tyra Biosciences Inc.'s Potential Securities Fraud And Affected Investors Can Participate

Aug 24, 2024, 11:00 AM EDT - 1 year ago

Tyra Biosciences Inc. Shareholders Can Reach Out To The Schall Law Firm About An Investigation Into Possible Breaches Of Securities Laws

Aug 23, 2024, 11:00 AM EDT - 1 year ago

Investors With Losses In Tyra Biosciences Inc. Are Urged To Join An Inquiry Into Possible Securities Fraud With The Schall Law Firm

anachartanalyst Dec. 16 at 8:02 PM

$TYRA https://anachart.com/wp-content/uploads/ana_temp/1765915319_soc-img.jpg

0 · Reply

JarvisFlow Dec. 16 at 12:36 PM

Wedbush updates rating for Tyra Biosciences ( $TYRA ) to Outperform, target set at 30 → 37.

0 · Reply

Quantumup Dec. 16 at 12:14 PM

0 · Reply

Quantumup Dec. 4 at 1:26 PM

0 · Reply

destinyb5 Dec. 3 at 6:18 PM

$TYRA $SPY

0 · Reply

PaulLaurent Nov. 24 at 8:06 AM

1 · Reply

BEATOFtheMARKET Nov. 23 at 9:09 PM

$TWST $TXG $TXT $TYLG 🔥 $TYRA 🔥

0 · Reply

FinJay Nov. 23 at 3:01 PM

1 · Reply

monkfruit Nov. 21 at 4:46 PM

$TYRA Sold for a 51.64% gain. 🤯 This stock way outperformed my expectations. Might keep going up, but I'm happy here. https://stocktwits.com/monkfruit/message/628677685

0 · Reply

StockScanners Nov. 21 at 4:30 AM

$TYRA keep watch if this holds above 20.35

0 · Reply

BioTechHealthX Nov. 21 at 12:14 AM

$TYRA Tyra Biosciences (NASDAQ:TYRA) enters 2026 with $274.9M in cash and multiple Phase 2 readouts, including pivotal data for dabogratinib in achondroplasia and bladder cancer. Learn why investors are watching this FGFR3-focused biotech preparing for its biggest year yet. https://biotechhealthx.com/biotech-news/tyra-biosciences-tyra-the-274-9m-precision-biotech-betting-big-on-fgfr3-breakthroughs-in-2026/

0 · Reply

topstockalerts Nov. 20 at 8:51 PM

$TYRA let's close strong.. 🏦

0 · Reply

Doozio Nov. 20 at 8:05 PM

$TYRA 🐒🍌🧠⏰♾️

0 · Reply

kshonstocks Nov. 20 at 7:59 PM

$TYRA something right

0 · Reply

topstockalerts Nov. 20 at 6:35 PM

$TYRA it wants to squeeze higher.. ✅

0 · Reply

monkfruit Nov. 20 at 6:17 PM

$TYRA 😳

0 · Reply

Doozio Nov. 20 at 2:41 AM

All the way up YO Roger $TYRA as long as it’s not a faaatch 💣 that’s up it!

0 · Reply

Doozio Oct. 15 at 10:34 PM

Chop chop huckleberries $TYRA. It’s 🐒🍌🧠⏰♾️

0 · Reply

monkfruit Sep. 15 at 1:41 PM

Picked up $TYRA

0 · Reply

Quantumup Sep. 10 at 12:37 PM

Oppenheimer⬆️the PT on $TYRA to $36 from $30 reiterated at an Outperform and said, we hosted $TYRA for meetings in Boston on Monday. [ $REGN $PFE $RHHBY $MRK BMY ] In each meeting, management made the case for why dabogratinib's combined market opportunity exceeds $10B. That's nearly Regeneron-esque revenues. Despite that, investors still complain that all the major catalysts aren't until 2026. Fine. But don't expect to find shares at this price -with a sub-$500M enterprise value-next year. This is one of the most de-risked stories we've ever covered because the roles that FGFR3 plays in both cancer and bone growth are so well-validated. What we hadn't truly appreciated was the sheer size of the market. We are revamping our model to increase peak sales in both NMIBC and Achondroplasia, while still feeling that our numbers leave room for upside. Reiterate Outperform; PT to $36.

0 · Reply

JarvisFlow Sep. 3 at 4:54 PM

Raymond James has adjusted their stance on Tyra Biosciences ( $TYRA ), setting the rating to Strong Buy with a target price of 35.

0 · Reply

kshonstocks Sep. 3 at 11:05 AM

eyeing $TYRA this morning in this reco--Tyra Biosciences initiated with a Strong Buy at Raymond James 16:40 TYRA Raymond James initiated coverage of Tyra Biosciences with a Strong Buy rating and $35 price target. Tyra's unique SNAP development platform, as validated with the first discovery candidate, TYRA-300, is "potentially best-in-class," says the analyst, who sees "multi-billion-dollar revenue potential" in the indications being investigated. Read more at: https://thefly.com/n.php?id=4191802

0 · Reply

Market Cap	1.38B
Revenue (ttm)	0.00
Net Income (ttm)	-86.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	200,200
Avg Vol	449,700
Day's Range	N/A - N/A
Shares Out	53.37M
Stochastic %K	94%
Beta	1.09
Analysts	Strong Sell
Price Target	$33.00